The role of vacuum-assisted closure (VAC) therapy in the management of FOURNIER'S gangrene: a retrospective multi-institutional cohort study.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 21 01 2020
accepted: 14 03 2020
pubmed: 3 4 2020
medline: 6 8 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

To explore the role of vacuum assisted closure (VAC) therapy versus conventional dressings in the Fournier's gangrene wound therapy. This is a retrospective multi-institutional cohort study. Data of 92 patients from nine centers between 2007 and 2018 were retrospectively analyzed. After surgery, patient having a local or a disseminated FG were managed with VAC therapy or with conventional dressings. The 10-weeks wound closure cumulative rate and OS were analyzed. Of the 92 patients, 62 (67.4%) showed local and 30 (32.6%) a disseminated FG. After surgery, 19 patients (20.7%) with local and 14 (15.2%) with disseminated FG underwent to VAC therapy; 43 (46.7%) with local and 16 (17.4%) with disseminated FG were treated using conventional dressings. The multivariable logistic regression analysis demonstrated that the VAC in patients with disseminated FG led to a higher cumulative rate of wound closure than patients treated with no-VAC (OR = 6.5; 95% CI 1.1-37.4, p = 0.036). The Kaplan-Meier survival curves for the OS showed a significant difference between no-VAC patients with local and disseminated FG (OS rate at 90 days 0.90, 95% CI 0.71-0.97 vs 0.55, 95% CI 0.24-0.78, respectively; p = 0.039). Cox regression confirmed that no-VAC patients with disseminated FG showed the lowest OS (hazard ratio adjusted for sex and age HR = 3.4, 95% CI 1.1-10.4; p = 0.033). In this large cohort study, VAC therapy in patients with disseminated FG may offer an advantage in terms of 10-weeks wound closure cumulative rate and OS at 90 days after initial surgery.

Identifiants

pubmed: 32236663
doi: 10.1007/s00345-020-03170-7
pii: 10.1007/s00345-020-03170-7
pmc: PMC7223519
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

121-128

Références

Fournier JA (1883) Gangrene foudroyante de la verge. Med Pract 4:589–597
Mallikarjuna MN, Vijayakumar A, Patil VS, Shivswamy BS (2012) Fournier's gangrene: current practices. ISRN Surg 2012:942437
doi: 10.5402/2012/942437
Smith GL, Bunker CB, Dinneen MD (1998) Fournier’s gangrene. Br J Urol 81(3):347–355
doi: 10.1046/j.1464-410x.1998.00532.x
Sorensen MD, Krieger JN (2016) Fournier’s gangrene: epidemiology and outcomes in the general US population. Urol Int 97:249
doi: 10.1159/000445695
Stone HH, Martin JD Jr (1972) Synergistic necrotizing cellulitis. Ann Surg 175:702–711
doi: 10.1097/00000658-197205000-00010
Rodríguez Alonso A, Pérez García MD, Núñez López A, Ojea Calvo A, Alonso Rodrigo A, Rodríguez Iglesias B et al (2000) Fournier’s gangrene: anatomo-clinical features in adults and children. Therapy update. Actas Urol Esp 24(4):294–306
doi: 10.1016/S0210-4806(00)72452-1
Eke N (2000) Fournier's gangrene: a review of 1726 cases. Br J Surg 87:718–728
doi: 10.1046/j.1365-2168.2000.01497.x
Chennamsetty A, Khourdaji I, Burks F, Killinger KA (2015) Contemporary diagnosis and management of Fournier's gangrene. Ther Adv Urol 7(4):203–215
doi: 10.1177/1756287215584740
Pastore AL, Palleschi G, Ripoli A, Silvestri L, Leto A, Autieri D et al (2013) A multistep approach to manage Fournier’s gangrene in a patient with unknown type II diabetes: surgery, hyperbaric oxygen, and vacuum assisted closure therapy: a case report. J Med Case Rep 7:1
doi: 10.1186/1752-1947-7-1
Bonkat G, Bartoletti RR, Bruyère F et al (2019) European Association of Urology - Infections in Urology Guidelines Panel, Copenhagen, EAU Guidelines Office, Arnhem. ISBN 978-94-92671-02-8
Ozturk E, Ozguc H, Yilmazlar T (2009) The use of vacuum assisted closure therapy in the management of Fournier's gangrene. Am J Surg 197(5):660–665 (discussion 665)
doi: 10.1016/j.amjsurg.2008.04.018
Hagedorn JC, Wessells H (2017) A contemporary update on Fournier's gangrene. Nat Rev Urol 14(4):205–214
doi: 10.1038/nrurol.2016.243
Yanaral F, Balci C, Ozgor F, Simsek A, Onuk O, Aydin M et al (2017) Comparison of conventional dressings and vacuum-assisted closure in the wound therapy of Fournier's gangrene. Arch Ital Urol Androl 89(3):208–211
doi: 10.4081/aiua.2017.3.208
Ozkan O, Koksal N, Altinli E, Celik A, Uzun M, Cikman O (2016) Fournier’s gangrene current approaches. Int Wound J 13(5):713–716
doi: 10.1111/iwj.12357
Yücel M, Özpek A, Başak F, Kılıç A, Ünal E, Yüksekdağ S et al (2017) Fournier's gangrene: a retrospective analysis of 25 patients. Ulus Travma Acil Cerrahi Derg 23(5):400–404
pubmed: 29052826
Czymek R, Schmidt A, Eckmann C, Bouchard R, Wulff B, Laubert T et al (2009) Fournier's gangrene: vacuum-assisted closure versus conventional dressings. Am J Surg 197(2):168–176
doi: 10.1016/j.amjsurg.2008.07.053
Korkut M, Içöz G, Dayangaç M, Akgün E, Yeniay L, Erdoğan O et al (2003) Outcome analysis in patients with Fournier's gangrene: report of 45 cases. Dis Colon Rectum 46(5):649–652
doi: 10.1007/s10350-004-6626-x
Assenza M, Cozza V, Sacco E, Clementi I, Tarantino B, Passafiume F et al (2011) VAC (Vacuum Assisted Closure) treatment in Fournier's gangrene: personal experience and literature review. Clin Ter 162(1):e1–5
pubmed: 21448535
Cuccia G, Mucciardi G, Morgia G, Stagno d'Alcontres F, Galì A et al (2009) Vacuum-assisted closure for the treatment of Fournier's gangrene. Urol Int 82(4):426–431
doi: 10.1159/000218532
Saijo S, Kuramoto Y, Yoshinari M (1990) Extremely extended Fournier’s gangrene. Dermatologica 181:228–232
doi: 10.1159/000247930
Oguz A, Gümüş M, Turkoglu A, Bozdağ Z, Ülger BV, Agaçayak E et al (2015) Fournier's gangrene: a summary of 10 years of clinical experience. Int Surg 100(5):934–941
doi: 10.9738/INTSURG-D-15-00036.1
Korhonen K (2000) Hyperbaric oxygen therapy in acute necrotizing infections with a special reference to the effects on tissue gas tensions. Ann Chir Gynaecol 89(suppl):7ff
Pizzorno R, Bonini F, Donelli A (1997) Hyperbaric oxygen therapy in the treatment of Fournier’s disease in 11 male patients. J Urol 158:837–840
doi: 10.1016/S0022-5347(01)64331-3
Capelli-Schellpfeffer M, Gerber GS (1999) The use of hyperbaric oxygen in urology. J Urol 162:647–654
doi: 10.1097/00005392-199909010-00002
Shupak A, Shoshani O, Goldenberg I (1995) Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery 118:873–878
doi: 10.1016/S0039-6060(05)80278-8
Wagner S, Greco F, Hoda MR, Kawan F, Heynemann H, Fornara P (2011) Is intensive multimodality therapy the best treatment for fournier gangrene? Evaluation of clinical outcome and survival rate of 41 patients. Surg Infect (Larchmt) 12(5):379–383
doi: 10.1089/sur.2010.091
Lambert KV, Hayes P, McCarthy M (2005) Vacuum assisted closure: a review of development and current applications. Eur J Vasc Endovasc Surg 29:219–226
doi: 10.1016/j.ejvs.2004.12.017

Auteurs

Valerio Iacovelli (V)

Urology Unit, San Carlo Di Nancy Hospital, GVM Care and Research, Via Aurelia 275, 00100, Rome, Italy. valerio.iacovelli85@gmail.com.
Department of Surgical Sciences, University Tor Vergata, Roma, Italy. valerio.iacovelli85@gmail.com.

Chiara Cipriani (C)

Urology Unit, San Carlo Di Nancy Hospital, GVM Care and Research, Via Aurelia 275, 00100, Rome, Italy.

Marco Sandri (M)

Data Methods and System Statistical Laboratory, University of Brescia, Brescia, Italy.

Roberta Filippone (R)

Department of Surgical Sciences, University Tor Vergata, Roma, Italy.

Antonella Ferracci (A)

Department of Surgery, Policlinico Tor Vergata Foundation, Rome, Italy.

Salvatore Micali (S)

Department of Urology, Ospedale Policlinico E Nuovo Ospedale Civile S.Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.

Bernardo Rocco (B)

Department of Urology, Ospedale Policlinico E Nuovo Ospedale Civile S.Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.

Stefano Puliatti (S)

Department of Urology, Ospedale Policlinico E Nuovo Ospedale Civile S.Agostino Estense Modena, University of Modena and Reggio Emilia, Modena, Italy.

Paolo Ferrarese (P)

Urology Unit, San Bortolo Hospital, Vicenza, Italy.

Giuseppe Benedetto (G)

Urology Unit, San Bortolo Hospital, Vicenza, Italy.

Andrea Minervini (A)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.

Andrea Cocci (A)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.

Antonio Luigi Pastore (AL)

Department of Urology, ICOT Latina, Latina, Italy.

Yazan Al Salhi (Y)

Department of Urology, ICOT Latina, Latina, Italy.

Alessandro Antonelli (A)

Urology Unit, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University Hospital of Verona, Verona and Confortini, Borgo General Hospital, Trento, Italy.

Tonino Morena (T)

Urology Unit, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University Hospital of Verona, Verona and Confortini, Borgo General Hospital, Trento, Italy.

Alessandro Volpe (A)

Department of Urology, University of Eastern Piedmont, Maggiore Della Carità Hospital, Novara, Italy.

Filippo Poletti (F)

Department of Urology, University of Eastern Piedmont, Maggiore Della Carità Hospital, Novara, Italy.

Antonio Celia (A)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.

Guglielmo Zeccolini (G)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.

Costantino Leonardo (C)

Department of Urology, La Sapienza University of Rome, Rome, Italy.

Flavia Proietti (F)

Department of Urology, La Sapienza University of Rome, Rome, Italy.

Enrico Finazzi Agrò (E)

Department of Surgical Sciences, University Tor Vergata, Roma, Italy.

Pierluigi Bove (P)

Urology Unit, San Carlo Di Nancy Hospital, GVM Care and Research, Via Aurelia 275, 00100, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH